Article
Deconvoluting Kinase Inhibitor Induced Cardiotoxicity
26 Apr 2017
Abstract excerpt
Many drugs designed to inhibit kinases have their clinical utility limited by cardiotoxicity-related label warnings or prescribing restrictions. While this liability is widely recognized, designing safer kinase inhibitors (KI) requires knowledge of the causative kinase(s). Efforts to unravel the kinases have encountered pharmacology with nearly prohibitive complexity. At therapeutically relevant concentrations,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
